Yearly zoledronic acid at lower-than-standard doses increases bone density

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. The new research findings will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.

"Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease ," said Andrew Grey, MD, principal investigator of the study and an associate professor of medicine at the University of Auckland in Auckland, New Zealand. "If that is so, it would reduce the health care costs of treating osteoporosis, a common condition, and may reduce the likelihood of side effects of the medication."

Currently the manufacturers of zoledronic acid, also called zoledronate, recommend a once-yearly intravenous infusion of 5 milligrams (mg) for prevention of fractures in people with osteoporosis. Women with mild bone loss, or osteopenia, who take the drug to prevent osteoporosis receive a 5-mg dose every other year.

The investigators randomly allocated 180 with osteopenia to receive a single treatment with either placebo (an inactive substance) or 1 mg, 2.5 mg or 5 mg of zoledronate. None of the women had previously received treatment with zoledronate or any other bisphosphonate medication, according to Grey. The women had tests of their at the lumbar spine (lower back) and the hip before treatment and during one year after treatment.

One year after treatment, bone density was significantly increased in each of the zoledronate groups, compared with the . The percentage improvement in spine bone density was similar for each zoledronate group, according to the authors: 3.5 percent for the 1 mg dose, 4 percent for the 2.5 mg dose and 3.6 percent for the standard 5.0 mg dose.

Additionally, blood markers of , or bone breakdown, were decreased in the zoledronate groups, compared with the placebo group.

"These results show clearly beneficial effects on and metabolism from lower doses of zoledronate, administered annually," Grey said. "Clinical trials should be undertaken to determine the ability of low doses of zoledronate to prevent fractures."

Explore further

Vitamin K does not stem BMD decline in postmenopausal women with osteopenia

Citation: Yearly zoledronic acid at lower-than-standard doses increases bone density (2011, June 6) retrieved 16 November 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments